BRCA1 and breast cancer: Genomic scar signatures associated with HRD; namely TAI (telomeric allelic imbalance), LST (large scale transition), and HRD-LOH (loss of heterozygosity), have been described as useful tools to identify BRCA1/2-deficient BC, which in turn could benefit the patients with platinum or PARP (Poly ADP-Ribose Polymerase) inhibitor therapies [10,20,21,23].